HIV prevention drug lenacapavir safe and effective in trial
Summary: A Phase 3 clinical trial found lenacapavir, a novel injectable HIV prevention drug, to be safe and 100% effective when administered twice a year to cisgender women. This breakthrough could revolutionize HIV prevention strategies, potentially reducing new infections significantly. Lenacapavir inhibits HIV replication by targeting the virus's capsid protein. The drug's bi-annual dosing schedule simplifies prevention regimens. Regulatory approvals and pricing remain key challenges for widespread implementation.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings